Skip to main content

cyclin dependent kinase inhibitor 2A

The CDKN2A gene provides instructions for making several proteins. The most well-studied are the p16(INK4A) and the p14(ARF) proteins. Both function as tumour suppressors, which means they keep cells from growing and dividing too rapidly or in an uncontrolled way. Both proteins are also involved in stopping cell division in older cells (senescence).

Video picks for Genes
Video library

Normal function

The CDKN2A gene provides instructions for making several proteins. The most well-studied are the p16(INK4A) and the p14(ARF) proteins. Both function as tumour suppressors, which means they keep cells from growing and dividing too rapidly or in an uncontrolled way. Both proteins are also involved in stopping cell division in older cells (senescence).

The p16(INK4A) protein attaches (binds) to two other proteins called CDK4 and CDK6. These proteins help regulate the cell cycle, which is the cell's way of replicating itself in an organized, step-by-step fashion. CDK4 and CDK6 normally stimulate the cell to continue through the cycle and divide. However, binding of p16(INK4A) blocks CDK4's or CDK6's ability to stimulate cell cycle progression. In this way, p16(INK4A) controls cell division. Cells begin to produce p16(INK4A) when they are no longer able to undergo cell division.

The p14(ARF) protein protects a different protein called p53 from being broken down. The p53 protein is an important tumour suppressor that is essential for regulating cell division, senescence, and self-destruction (apoptosis). By protecting p53, p14(ARF) also helps prevent tumour formation. The p14(ARF) and p53 proteins are often made in cells that are unable to undergo cell division.

Conditions referring to this gene or chromosome

Other names

ARF

CDK4 inhibitor p16-INK4

CDK4I

CDKN2

cell cycle negative regulator beta

CMM2

cyclin-dependent kinase 4 inhibitor A

cyclin-dependent kinase inhibitor 2A

cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)

cyclin-dependent kinase inhibitor 2A isoform p12

cyclin-dependent kinase inhibitor 2A isoform p14ARF

cyclin-dependent kinase inhibitor 2A isoform p16gamma

cyclin-dependent kinase inhibitor 2A isoform p16INK4a

INK4

INK4A

MLM

MTS-1

MTS1

multiple tumour suppressor 1

P14

P14ARF

P16

P16-INK4A

P16INK4

P16INK4A

P19

P19ARF

TP16

Patient picks for Genes

Related patient information and medicines

Pompholyx

Patient information leaflet

Pompholyx

Pompholyx is a type of eczema where there are itchy blisters on the hands and feet, followed by inflamed and dry skin. The condition is usually long-term, with symptoms that come and go at various times. In some cases it has been shown to be helpful for the treatment of pompholyx. Janus Kinase (JAK) inhibitors : these medications, available as.

Mouth cancer

Patient information leaflet

Mouth cancer

Dia... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their GP for suspected cancer. To confirm the diagnosis It is likely that you will need a biopsy. Cetuximab is an.

Chronic myeloid leukaemia

Patient information leaflet

Chronic myeloid leukaemia

Chronic myeloid leukaemia (CML) is sometimes called chronic myelogenous leukaemia, chronic granulocytic leukaemia, or chronic myelocytic leukaemia. What is... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Mastocytosis and mast cell disorders

Patient information leaflet

Mastocytosis and mast cell disorders

If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on the immune system (such as interferon), bone marrow transplant or... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.

Mitral regurgitation

Patient information leaflet

Mitral regurgitation

The mitral valve is a heart valve that lies between the left atrium and left ventricle. ...eart - mitral valve incompetence i88_l.jpg What is mitral regurgitationAlthough medicines cannot correct mitral regurgitation, some medicines may be prescribed to help ease symptoms, or to help prevent complications by managing your blood pressure - for.

Myelofibrosis

Patient information leaflet

Myelofibrosis

The gene mutation that occurs in most people affected by myelofibrosis is a mutation in Janus Kinase 2 (JAK2). A group of medicines called JAK inhibitors (JAKi) may be given to some people with myelofibrosis to treat severe anaemia or an enlarged spleen. Dr Sarah Jarvis, December 2021 NICE guidance on drug treatments for myelofibrosis Fedratinib.

Further reading and references

Article history

The information on this page is written and peer reviewed by qualified clinicians.
  • 20 Mar 2023 | Latest version
  • 1 Jul 2018 | Originally published

Join the conversation

Share your thoughts or experiences with others in our patient communities.

Disclaimer: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Online pharmacy, treatments and health services

Simple access to trusted treatments and health services online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Sign up to the Patient newsletter

Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.